Clinical AI Governance · ELSA AI
Your clinic is alreadyusing AI. Could you proveit is under control?
ELSA AI helps private GP, dental and specialist clinics discover, evidence and govern the AI tools already in use across the practice — ambient scribes, ChatGPT, Microsoft Copilot, transcription tools and shadow AI on personal devices.
In four working days, the Clinical AI Exposure Diagnostic™ gives the practice owner and board a documented view of what AI is in use, where patient data may be involved, what evidence is missing, and what to do in the next 30 days. Senior-led. Founder-delivered. No template-and-invoice model.
Fixed fee £4,500–£6,500 + VAT.
Common triggers
Advisory governance support only. Not legal advice, CQC certification, ICO approval, insurer coverage advice, MDO indemnity advice, or clinical safety case sign-off. Final decisions remain with the client's accountable officers.
Built for Private Healthcare Providers Using AI with Patient Data
Private GP & GP-Led Clinics
For CQC-regulated private GP, executive health and multi-disciplinary clinics using or considering ChatGPT, Copilot, ambient scribes, AI transcription or admin automation.
Clinics Using Ambient Scribes
For clinics piloting or rolling out tools such as Heidi, Tortus, Accurx Scribe, Dragon DAX, Tandem, Nabla or similar clinical transcription and note-generation tools.
Dental Practices & Groups
For dental practices, orthodontic clinics, implant clinics and dental groups using AI imaging, note drafting, transcription, patient communication or marketing automation.
Specialist Clinics
For doctor-led dermatology, aesthetics, diagnostics, fertility, ophthalmology and specialist clinics using AI with images, consultation notes, correspondence or patient workflows.
From Shadow AI to a Documented Governance Position
Most clinics do not start with a clean AI programme. They start with informal use: an ambient scribe in consultation, ChatGPT for drafting, Copilot for admin, transcription tools in meetings and AI-enabled platforms introduced by suppliers. The governance risk is having no documented position when someone asks how that AI use is controlled.
That often surfaces as an evidence gap  no register, no DPIA status, no supplier data position, no patient transparency wording, no human oversight procedure and no board-level view.
AI Tool Discovery
Identify declared and suspected AI use across clinical, admin, marketing and operational workflows, including ChatGPT, Copilot, ambient scribes, transcription tools and AI-enabled SaaS.
Patient Data Exposure
Map whether clinical notes, consultation audio, patient images, identifiers, correspondence or special category health data may be processed by AI tools.
DPIA & Privacy Evidence
Check whether DPIA screening, privacy notices, lawful-basis documentation, RoPA indicators and patient transparency evidence exist or require DPO/legal review.
Vendor Evidence
Track supplier evidence gaps across DPAs, data residency, sub-processors, retention, training-data use, security assurance and international transfer indicators.
Clinical Oversight
Review whether clinicians remain accountable for AI-generated outputs before they are relied upon, sent externally or entered into the patient record.
Board-Ready Evidence Pack
Receive a plain-English findings report, RAG exposure map, tool inventory, DPIA readiness note, vendor tracker, disclosure readiness note and 30-day action plan.
How the Clinical AI Exposure Diagnostic™ Works
A focused 4-working-day assessment that shows what AI is being used, where patient data may be involved, what evidence is missing and what should be prioritised in the next 30 days.
Diagnostic first, Launchpad second, Sentinel third: the Diagnostic identifies current AI use and priority evidence gaps; the Launchpad converts findings into a working governance baseline; Sentinel keeps the evidence current.
Discover AI Use
Day 1
Leadership intake and evidence request
Confidential, role-level staff AI use survey
Review of known tools, trials and supplier platforms
Initial shadow AI and patient-data exposure mapping
Assess Governance Evidence
Days 2–3
AI tool and use-case inventory
DPIA readiness and patient data exposure review
Vendor data position and evidence tracker
Ambient scribe assessment where applicable
Human oversight and patient transparency review
Deliver Board-Ready Actions
Day 4
Board Findings Report
One-page RAG Exposure Map
30-Day Priority Action Plan
MDO, PMI and insurer disclosure readiness note
Source and guidance mapping appendix
What You Receive in the 4-Day Diagnostic
- Board Findings Report
- One-page RAG Exposure Map
- AI Tool and Use-Case Inventory
- DPIA Readiness and Patient Data Exposure Note
- Vendor Data Position and Evidence Tracker
- Ambient Scribe Assessment Sheet, where applicable
- MDO, PMI and Insurer Disclosure Readiness Note
- 30-Day Priority Action Plan
- Source and Guidance Mapping Appendix
Why Private Clinics Engage ELSA AI
The Diagnostic does not claim to fix every AI risk in four days. It gives leadership a documented starting position: what AI is in use, what data it touches, what evidence is missing and what actions should be taken next.
Answer DPO and Board Questions
Know what AI is being used and where evidence is missing.
AI tool and use-case inventory
Patient data exposure note
DPIA readiness indicators
Board-ready findings report
Prepare Before Ambient Scribe Rollout
Treat scribes as governed clinical technology, not simple dictation.
Supplier evidence tracker
Patient transparency review
Human oversight workflow check
DCB0160-style evidence structure where relevant
Reduce Shadow AI Exposure
Move informal use into a controlled governance position.
Confidential staff AI use survey
Approved, conditional and prohibited-use indicators
Personal-device and free-tier tool review
Priority actions for unmanaged exposure
Support Insurer, MDO and CQC Readiness
Prepare evidence before formal questions arrive.
Disclosure readiness note
Governance-standard source mapping
RAG exposure map
30-day owner-assigned action plan
A Practical AI Governance Pathway for Private Healthcare
Start with a fast exposure diagnostic. Remediate with a structured governance launchpad. Keep evidence current through quarterly review.
Clinical AI Exposure Diagnosticâ„¢
4 working days | £4,500–£6,500 + VAT
A senior-led assessment showing what AI tools are in use, what patient data they may touch, what governance evidence is missing and what actions should be prioritised in the next 30 days.
Outputs:
- Board Findings Report
- RAG Exposure Map
- AI Tool Inventory
- DPIA Readiness Note
- Vendor Evidence Tracker
- 30-Day Action Plan
Clinical AI Safe Usage Launchpadâ„¢
4–6 weeks | £14,500–£22,000 + VAT
Converts Diagnostic findings into a working AI governance baseline for review and adoption by the clinic's accountable officers.
Outputs:
- AI usage policy
- AI tool register
- Risk register
- Staff guidance
- Patient transparency wording
- Incident process
- Board evidence pack
AI Exposure Sentinelâ„¢
Quarterly retainer | £950/month or £10,500/year + VAT
Keeps the AI governance position current as tools, staff usage, vendor terms, insurer questions and regulatory expectations change.
Outputs:
- Quarterly reassessment
- Refreshed RAG map
- Updated tool register
- Evidence pack refresh
- Board/DPO advisory support
Faisal Ali, CISM, CRISC
Founder and Principal Consultant, ELSA AI
Senior-Led AI Governance for Regulated Healthcare
Every ELSA AI engagement is delivered personally by Faisal Ali, CISM, CRISC, Founder and Principal Consultant of ELSA AI.
Faisal is a senior cybersecurity, information risk and AI governance consultant with more than two decades of experience in regulated environments. His work focuses on practical evidence: what controls exist, what gaps remain, who owns the risk and what decision-makers need to see.
ELSA AI was built for organisations deploying third-party AI tools  not building AI models. The focus is on helping clinics move from informal or unmanaged AI use to a documented governance position that can be reviewed by the DPO, clinical lead, board, insurer, MDO or relevant adviser.
What this experience brings to clinics
- •Healthcare AI governance without unnecessary enterprise complexity
- •Clear evidence packs rather than abstract AI ethics documents
- •Cybersecurity and data protection discipline applied to real clinic workflows
- •Plain-English reports for owners, partners, boards and clinical leads
- •Advisory boundaries that protect the clinic and keep final sign-off with accountable officers
Clear Advisory Boundaries
ELSA AI provides advisory governance support. Final decisions on legal interpretation, DPIA sign-off, clinical safety documentation, MDO disclosure, insurer notification, regulatory engagement and risk acceptance remain with the clinic's accountable officers and advisers.
Not Legal or Regulatory Approval
ELSA AI does not provide legal advice, ICO approval, CQC approval, CQC certification or formal regulatory compliance certification.
Not Clinical Safety Sign-Off
ELSA AI can structure evidence and identify review points, but clinical safety ownership and DCB0160 sign-off remain with the client’s appointed clinical safety lead or responsible officer.
Not Insurer or MDO Advice
ELSA AI identifies governance evidence gaps and disclosure readiness indicators. It does not provide insurer coverage advice or MDO indemnity advice.
Need to Know What AI Is Already Happening in Your Clinic?
Start with a 20-minute discovery call. ELSA AI will confirm whether the Clinical AI Exposure Diagnosticâ„¢ is appropriate, what tools or workflows should be in scope and whether there is a time-sensitive trigger such as an ambient scribe rollout, DPO review, insurer renewal, MDO question, board meeting or CQC inspection.
Advisory governance support only. Not legal advice, regulatory approval, CQC certification, insurer advice, MDO indemnity advice or clinical safety case sign-off.